Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion

Figures & data

Table 1 Clinical characteristics of the patients at baseline

	SRD	No-SRD	P-value
Gender (M/F), n	21	31	0.78
Age (y), mean ± SD	64.7±4.9	65.4±4.6	0.58
Right eye/left eye, n	13/8	17/14	0.61
Superior/inferior temporal, n	14/7	21/10	0.20
Duration of BRVO (months), mean ± SD	2.3±2.1	2.7±1.9	0.63
Mean CMT (µm, mean ± SD	451±62.2	383.5±37.2	<0.05
Mean VA (LogMAR), mean ± SD	0.87±0.26	0.69±0.25	<0.05

Abbreviations: BRVO, branch retinal vein occlusion; CMT, central macular thickness; F, female; LogMAR, logarithm of the minimum angle of resolution; M, male; SRD, serous retinal detachment; VA, visual acuity.

Figure 1 First month macular thickness changes of the groups with serous retinal detachment (SRD) and without SRD after single-dose intravitreal ranibizumab injection.

Figure 2 First month visual acuity changes of the groups with serous retinal detachment (SRD) and without SRD after single-dose intravitreal ranibizumab injection.